Pravastatin Sodium Tablets

It is a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase). HMG-CoA reductase is the rate-limiting enzyme in the initial stage of cholesterol biosynthesis. It reversibly inhibits HMG-CoA reductase, thereby inhibiting cholesterol biosynthesis. It exerts its lipid-lowering effect in two aspects. First, it reduces the amount of intracellular cholesterol to a certain extent by reversibly inhibiting the activity of HMG-CoA reductase, leading to an increase in the number of low-density lipoprotein (LDL) receptors on the cell surface, thereby strengthening the receptor-mediated decomposition of LDL and the clearance of LDL in the blood; second, it inhibits the synthesis of LDL precursor-very low-density lipoprotein (VLDL-C) in the liver, thereby inhibiting the generation of LDL-C.

Pravastatin sodium. The molecular formula is C23H35NaO7 and the molecular weight is 446.52.

Reddish bare flakes with a cut line on one side, odorless, slightly bitter taste.

Hyperlipidemia, familial hypercholesterolemia.

The starting dose for adults is 10 mg to 20 mg/time, once a day, taken before bedtime, with a maximum daily dose of 40 mg.

Adverse reactions may include mild elevation of transaminase, rash, myalgia, headache, chest pain, nausea, vomiting, diarrhea, fatigue, etc.

It is contraindicated for people with allergies, active hepatitis or persistently elevated liver function tests, as well as pregnant and lactating women.

Precautions for children: Not clear. Precautions for pregnancy and lactation: Contraindicated for pregnant and lactating women. Precautions for the elderly: Elderly patients should consider the possibility of reduced renal function due to advanced age, and should regularly check renal function, observe patient symptoms, and administer medication with caution.

When this product is given one hour before or four hours after taking cholestyramine or one hour before taking colestipol and a standard meal, its bioavailability and therapeutic effect are not significantly reduced clinically. If either of the above two drugs is taken at the same time, the bioavailability of this product decreases by 40% to 50%. When used in combination with antipyrine, it does not affect the clearance of antipyrine by the cytochrome P450 system. Since this product does not induce the action of liver drug metabolizing enzymes, it will not produce significant interactions with other drugs metabolized by the cytochrome P450 system (such as phenytoin sodium, quinidine). When used in combination with warfarin, the bioavailability parameters of this product at steady state do not change, and this product does not change the binding of warfarin to plasma proteins. Long-term use of these two drugs does not produce any changes in the anticoagulant effect of warfarin. In the study of interaction with aspirin, antacids (given one hour before taking this product), cimetidine, gemfibrozil, niacin or probucol, no significant difference was found in the bioavailability of this product. Taking antacids and cimetidine can change the blood concentration of this product, but it does not affect the efficacy. No obvious interaction was found when it was used in combination with diuretics, antihypertensive drugs, digitalis, converting enzyme inhibitors, calcium channel blockers, beta-receptor blockers or nitroglycerin.

Keep in a light-proof and airtight container.

20 mg

36 months

Daiichi Sankyo Pharmaceutical (SHANGHAI) Co., Ltd.

• Founded in:

  1999-11-18

• Address:

  No. 500, Juli Road, China (Shanghai) Pilot Free Trade Zone

• Tax NO.:

  91310000607410671R

• Registered Funds:

  $53 million

• Website:

  Log in to view

• Email:

  Log in to view